Google and Sanofi partner in diabetes

The search giant and the drugmaker will develop new tools to monitor the disease and improve patient outcomes.

Five things for pharma marketers to know: Tuesday, September 1

Amgen gives hefty discount to Repatha in Europe; Valeant partners with AstraZeneca on controversial psoriasis drug; Pfizer now offers single packages of Viagra

Social Engagement: Leveling the Field

Social media has the potential to elevate challenger brands to the highest step on the podium. But with many companies still languishing in the blocks, ...
Welcome to CampaignCheckup! CampaignCheckup is our new, monthly podcast series dedicated to examining the curious in Rx marketing and advertising. For our inaugural episode, "Cardiac Resuscitation," Larry Dobrow, senior editor, MM&M, and Michael Maher, president, ID Health, sit down to discuss the DTC campaign for Bristol-Myers Squibb's and Pfizer's oral blood thinner Eliquis.

Latest

Domanico, founding creative behind Draftfcb Healthcare, passes away at 74

Domanico, founding creative behind Draftfcb Healthcare, passes away at 74

The longtime creative director was instrumental in building the powerhouse agency that is now called FCB Health.

Is It Finally Time for Pharma to Change the Way It Uses Facebook?

Is It Finally Time for Pharma to Change the Way It Uses Facebook?

Pharma has hidden behind the ability to turn commenting off on Facebook pages, allowing marketers to use the channel much as they would a typical web page.

Pharma sales forces should act more like 'outcomes advocates'

Pharma sales forces should act more like 'outcomes advocates'

Sales reps that focus on creating value for HCPs could find new opportunities and improved access to those physicians, according to Accenture.

Five things for pharma marketers to know: Monday, August 31

Five things for pharma marketers to know: Monday, August 31

Kim Kardashian posts corrective information on Instagram and Twitter; DPP-4 inhibitors are linked to joint pain; doctors question off-label prescriptions of PCSK9 inhibitors

Five things for pharma marketers to know: Friday, August 28

Five things for pharma marketers to know: Friday, August 28

Amgen's Repatha receives FDA nod; Mylan shareholders vote in favor of Perrigo deal; doctors push for below-average price of experimental cancer drug

Washington Insider: A New Report

Washington Insider: A New Report

Back Talk: Hail to the . . . CEO?

Back Talk: Hail to the . . . CEO?

Private View: Bonnie Overton

Private View: Bonnie Overton

Partner Forum: Will predictive analytics sell?

Can predictive analytics, embedded into CRM, fulfill the promise on which closed-loop marketing fell short: Allow pharma to harness data from rep visits to make their upcoming digital sales pitches smarter?

The FDA approves second PCSK9 inhibitor, Repatha

The FDA approves second PCSK9 inhibitor, Repatha

Amgen's Repatha will come to market priced $500 lower than the cost of Sanofi and Regeneron's Praluent.

Sunovion prepares for FDA decision on Aptiom

Sunovion prepares for FDA decision on Aptiom

The FDA is expected to announce this week whether it has approved the epilepsy drug as a monotherapy for partial-onset seizures.

Agency Spotlight



Email Newsletters


Specialty medicines continue to be a hot category, one in which spending has surged behind products that treat medicine's most complex diseases. This eBook lays out the needs and hurdles along the specialty drug pathway, explaining how stakeholders are working to get meds into patients' hands and ease their experience. Click here to download.